"PTLA reps need to pound the pavement to get A on formularies. To realize the numbers we all hope for and the ramp we all hope for PTLA needs to execute!!! To think PTLA can do this in the EU with out a partner is crazy."
I said a long time ago that Portola marketing for both B and A would be a top down effort. What I meant by that is they would focus on getting the major organizations that publish treatment guidelines to include those drugs as the standard of care for their respective indications and then pursue an education campaign through presentations at conferences, publication in journals, CME (continuing medical education) and select advertising. I don't think face time with MD's and hospital staff pharmacists is going to be as effective as convincing KOL's and major hospital systems and then letting everyone else "catch up."
I have mixed feelings about Europe. A major partnering cedes some degree of ownership to the partner and reduces the buyout value of the company as a whole. Sales ramp up in Europe is always slow as each country wants to cut its own discount deal with the company and negotiations can be protracted.